Results 81 to 90 of about 24,893 (251)

Atypical hemolytic uremic syndrome : update on the complement system and what is new [PDF]

, 2010
Atypical hemolytic uremic syndrome (aHUS) is a rare disease of microangiopathic hemolytic anemia, thrombocytopenia, and predominant renal impairment. It is characterized by the absence of Shiga toxin-producing bacteria as a triggering factor.
Dickenmann, Michael, Hirt-Minkowski, Patricia, Schifferli, Jürg A.   +2 more
core   +1 more source

Paediatric renal transplantation: Paediatric surgeons' perspective

Surgical Practice, EarlyView.
Abstract Renal transplantation is the most effective treatment for paediatric end‐stage renal disease (ESRD), offering advantages in survival, growth and neurocognitive development that surpass other renal replacement therapies (RRT). The paediatric setting, however, introduces distinct complexities that distinguish it from adult practice.
Adrian Chi‐heng Fung, Mary Kim Elizabeth Tan Cudia, Ivy Hau‐yee Chan, Kenneth Kak‐yuen Wong   +3 more
wiley   +1 more source

Atypical Hemolytic Uremic Syndrome after SARS-CoV-2 Infection: Report of Two Cases

International Journal of Environmental Research and Public Health, 2022
Atypical hemolytic uremic syndrome (aHUS) is a life-threatening disease causing systemic thrombotic microangiopathy (TMA) due to the fact of complement dysregulation.
Iwona Smarz-Widelska, Małgorzata Syroka-Główka, Joanna Janowska-Jaremek, M. Koziol, W. Załuska   +4 more
semanticscholar   +1 more source

Reduced membrane attack complex formation in umbilical cord blood during Eculizumab treatment of the mother: a case report

BMC Nephrology, 2019
Background Atypical hemolytic uremic syndrome (aHUS) is a disorder of the microvasculature with hemolytic anemia, thrombocytopenia and acute kidney injury.
Subagini Nagarajah, Martin Tepel, Christian Nielsen, Kristian Assing, Yaseelan Palarasah, Lise Lotte Torvin Andersen, Lotte Borg Lange, Claus Bistrup   +7 more
doaj   +1 more source

Discontinuation of Eculizumab treatment after hematological remission in patients with atypical and drug-induced hemolytic uremic syndrome

Romanian Journal of Internal Medicine, 2022
Introduction. The aim was to evaluate the effect of therapeutic plasma exchange (TPE) and eculizumab on hematological and renal survival in atypical hemolytic uremic syndrome (aHUS), and additionally, to examine the reliability of discontinuation of ...
Yeter Hasan H., Derici Ulver, Arinsoy Turgay, Altok Kadriye, Erten Yasemin, Guz Galip   +5 more
doaj   +1 more source

First-line therapy in atypical hemolytic uremic syndrome: consideration on infants with a poor prognosis. [PDF]

, 2014
BackgroundAtypical hemolytic uremic syndrome (aHUS) is a rare and heterogeneous disorder. The first line treatment of aHUS is plasma therapy, but in the past few years, the recommendations have changed greatly with the advent of eculizumab, a humanized ...
A Szilagyi, Aspazija Sofijanova, Attila Szabó, C Loirat, CM Legendre, D Kavanagh, D Magen, F Fakhouri, F Fakhouri, G Ariceta, G Ariceta, György Reusz, J Caprioli, J Zuber, J Zuber, JM Campistol, Klaus Arbeiter, Krisztina Rusai, Lilla Szeifert, LM Geerdink, M Christmann, M Heurich, M Jozsi, M Lemaire, M Reti, MA Abrera-Abeleda, MA Dragon-Durey, Miklós Szabó, N Besbas, Nóra Szarvas, RA Gruppo, RL Ruebner, S Jung, Thomas Müller, Valbona Nushi-Stavileci, Velibor Tasic, Z Prohaszka, Zoltán Prohászka, Zoran Gucev, Ágnes Szilágyi   +39 more
core   +1 more source

Comparative 3‐Year Allograft Outcomes for Recipients of Kidneys From SARS‐CoV‐2 NAT‐Positive Donors

Transplant Infectious Disease, EarlyView.
In this retrospective single‐center study of 220 kidney transplants from SARS‐CoV‐2 NAT+, NAT+ with COVID as cause of death (CoV‐COD) and NATneg donors, we found no significant difference in rejection or kidney pathologies at 1 year, and death, graft loss, or eGFR at 3 years by CoV‐donor status.
Christine E. Koval, Mohamed Eltemamy, Nabin K. Shrestha, Leal Herlitz, Emilio D. Poggio, Alvin C. Wee   +5 more
wiley   +1 more source

Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: a case report [PDF]

, 2015
INTRODUCTION: Thrombotic microangiopathies are a group of diseases presenting as microangiopathic hemolytic anemia, thrombocytopenia and end-organ dysfunction.
Abdulkadir Unsal, Cuneyt Akgol, David Kavanagh, Ekrem Kara, Elbis Ahbap, Mustafa Sevinc, Tamer Sakaci, Taner Basturk, Tim HJ Goodship, Tuncay Sahutoglu, Vicky Brocklebank, Yener Koc   +11 more
core   +1 more source

Randomised, phase 1 evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of iptacopan in healthy volunteers

British Journal of Pharmacology, Volume 183, Issue 11, Page 2874-2889, June 2026.
Abstract Background and Purpose Overactivation of the alternative pathway (AP) underlies several diseases. Iptacopan is an oral, first‐in‐class, highly potent specific inhibitor of factor B, a key AP protease. Experimental Approach The analysis included data from two phase 1 randomised, volunteer‐blinded, placebo‐controlled studies: Study 1, a single ...
Irina Baltcheva, Guido Junge, Kenneth Kulmatycki, Robert Schmouder, Anna Schubart, Marie‐Anne Valentin   +5 more
wiley   +1 more source

Atypical Hemolytic Uremic Syndrome: A Case Report [PDF]

Cureus, 2019
Hemoytic uremic syndrome (HUS) is a rare type of thrombotic microangiopathies. Manifestations include thrombocytopenia, microangiopathic hemolytic anemia, and thrombi in small blood vessels. The prognosis is poor. Herein, we present a case of atypical HUS, which is very rare.
Mohammed, Sohaib K, Mubarik, Ateeq, Nadeem, Bilal, Khan, Khudadad, Muddassir, Salman   +4 more
openaire   +2 more sources